References
- McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 2006;332: 589–92
- Porst H. Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Int J Impot Res 2000;12(Suppl 4): S91–100
- Webber R. Erectile dysfunction. Clin Evid Concise 2005;14: 295–6
- Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil – a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997;9:187–92
- Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Eng J Med 1996;334:873–7
- Polak JM, Gu J, Mina S, Bloom SR.Vipergic nerves in the penis. Lancet 1981;2:217–19
- Shirai M, Maki A, Takanami M, et al. Content and distribution of vasoactive intestinal polypeptide (VIP) in cavernous tissue of human penis. Urology 1990;35:360–3
- Kim NN, Gallanc C, Dhir V. Potentiation of VIP induced relaxation by phentolamine in corpus cavernosum. Int J Impot Res 1998;10:S44
- Sandhu D, Curless E, Dean J, et al. A double blind placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phentolamine mesilate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Impot Res 1999;11:91–7
- Dinsmore WW, Gingell C, Hackett G, et al. Treating men with pre domin antly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesilate in a novel auto-injector system: a multi-centre double blind placebo controlled study. BJU Int 1999;83:274–9
- Dinsmore WW, Alderdice DK. Vasoactive intestinal polypeptide and phentolamine mesilate in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents. Br J Urol 1998;81:437–4